PREVAC/PREVAC-UP: Partnership for Research on Ebola VACcinations

The PREVAC trial is a Phase IIb randomized controlled trial evaluating the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) in children and adults in four West African countries (Guinea, Mali, Sierra Leone, and Liberia). As part of this consortium, the trial is being sponsored by Inserm, the NIH NIAID, and the LSHTM.Participants are randomized to receive either the Ad26.ZEBOV (rHAd26) vaccine with an MVA-BN-Filo (MVA) booster, the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without a booster, or a placebo. Long-term follow-up (M60) of participants, conducted with a high retention rate as part of the EDCTP2-funded PREVAC-UP project, is currently being analysed.